<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Dexrazoxane</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00380</strong>&#160; (APRD00090, DB02444)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, withdrawn</td></tr><tr><th>Description</th><td><p>An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]<br>
The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00380/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00380/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00380.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00380.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00380.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00380.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00380.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00380">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>WHO</td></tr><tr><td>4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IUPAC</td></tr><tr><td>Dexrazoxan</td><td>German</td><td>INN</td></tr><tr><td>Dexrazoxane</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>USAN, DCF, BAN</td></tr><tr><td>Dexrazoxano</td><td>Spanish</td><td>INN</td></tr><tr><td>Dexrazoxanum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Dexrazoxane hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001028/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001028/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001028">DBSALT001028</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Ao Nuo Xian</td><td>AosaiKang Pharmaceutical</td></tr><tr><td>Cardioxane</td><td>Novartis</td></tr><tr><td>Dexrazoxane</td><td>Raffo</td></tr><tr><td>Savene</td><td>TopoTarget</td></tr><tr><td>Totect</td><td>TopoTarget</td></tr><tr><td>Zinecard</td><td>Pfizer</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents">Antineoplastic Agents</a></li>
<li><a href="/mesh/chelating-agents">Chelating Agents</a></li>
<li><a href="/mesh/cardiovascular-agents">Cardiovascular Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>24584-09-6</td></tr><tr><th>Weight</th><td>Average: 268.2691<br>Monoisotopic: 268.11715502</td></tr><tr><th>Chemical Formula</th><td>C<sub>11</sub>H<sub>16</sub>N<sub>4</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>BMKDZUISNHGIBY-ZETCQYMHSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-[(2S)-1-(3,5-dioxopiperazin-1-yl)propan-2-yl]piperazine-2,6-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Piperazines</td></tr><tr><th>Subclass</th><td>Dioxopiperazines</td></tr><tr><th>Direct parent</th><td>Dioxopiperazines</td></tr><tr><th>Alternative parents</th><td>Diazinanes; N-unsubstituted Carboxylic Acid Imides; Secondary Carboxylic Acid Amides; Tertiary Amines; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>1,4-diazinane; carboxylic acid imide; carboxylic acid imide, n-unsubstituted; secondary carboxylic acid amide; carboxamide group; tertiary amine; polyamine; carboxylic acid derivative; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the dioxopiperazines. These are compounds containing a piperazine ring bearing two ketone groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.</td></tr><tr><th>Pharmacodynamics</th><td>Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose. Patients receiving anthracycline-derivative antineoplastic agents may experience three types of cardiotoxicity: acute transient type; chronic, subacute type (related to cumulative dose and has a more indolent onset later on); and a late-onset type that manifests years after therapy, mainly in patients that have been exposed to the drug as a child. Although the exact mechanism of anthracycline-induced cardiotoxicity is not known, it has shown to exert a variety of actions that may result in the development of cardiotoxicity. In animals, anthracyclines cause a selective inhibition of cardiac muscle gene expression for &#945;-actin, troponin, myosin light-chain 2, and the M isoform of creatine kinase. This may lead to myofibrillar loss associated with anthracycline-induced cardiotoxicity. Anthracyclines may also cause myocyte damage via calcium overload, altered myocardial adrenergic function, release of vasoactive amines, and proinflammatory cytokines. Furthermore, it has been suggested that the main cause of anthracycline-induced cardiotoxicity is associated with free-radical damage to DNA. The drugs intercalate DNA, chelate metal ions to produce drug-metal complexes, and generate superoxide radicals via oxidation-reduction reactions. Anthracyclines also contain a quinone structure that can undergo reduction via NADPH-dependent reactions to produce a semiquinone free radical that initiates a cascade of superoxide and hydroxide radical generation. Chelation of metal ions, particularly iron, by anthracyclines results in an anthracycline-metal complex that catalyzes the generation of reactive oxygen free radicals. This complex is a powerful oxidant that can initiate lipid peroxidation in the absence of oxygen free radicals. The toxicity induced by antrhacyclines may be exacerbated in cardiac cells, as these cells do not possess sufficient amounts of certain enzymes (e.g., superoxide dismutase, catalase, glutathione peroxidase) involved in detoxifying free radicals and protecting the cells from subsequent damage.</td></tr><tr><th>Mechanism of action</th><td>The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane (a prodrug) is converted intracellularly to a ring-opened bidentate chelating agent that chelates to free iron and interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. It should be noted that dexrazoxane may also be protective through its inhibitory effect on topoisomerase II.</td></tr><tr><th>Absorption</th><td>IV administration results in complete bioavailability.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>9 to 22.6 L/m^2</li>
</ul></td></tr><tr><th>Protein binding</th><td>Very low (</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Dexrazoxane is hydrolysed by the enzyme dihydropyrimidine amidohydrolase in the liver and kidney to active metabolites that are capable of binding to metal ions.</p></td></tr><tr><th>Route of elimination</th><td>Urinary excretion plays an important role in the elimination of dexrazoxane. Forty-two percent of the 500 mg/m2 dose of dexrazoxane was excreted in the urine.</td></tr><tr><th>Half life</th><td>2.5 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>7.88 L/h/m2 [dose of 50 mg/m2 Doxorubicin and 500 mg/m2 Dexrazoxane]</li>
	<li>6.25 L/h/m2 [dose of 60 mg/m2 Doxorubicin and 600 mg/m2 Dexrazoxane]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Intraperitoneal, mouse LD<sub>10</sub> = 500 mg/kg. Intravenous, dog LD<sub>10</sub> = 2 gm/kg.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8518</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.6387</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6144</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8766</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.6576</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9653</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7348</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8399</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7872</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5139</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9458</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8828</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9348</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7777</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9666</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9741</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9077
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.991
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4267 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.941
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8929
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Bedford laboratories div ben venue laboratories inc</li>
<li>Topotarget as</li>
<li>Pharmacia and upjohn co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li>Oso Biopharmaceuticals Manufacturing LLC</li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>